569 related articles for article (PubMed ID: 16322251)
1. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
2. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
Niu G; Carter WB
Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
[TBL] [Abstract][Full Text] [Related]
4. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
9. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.
Diaz N; Minton S; Cox C; Bowman T; Gritsko T; Garcia R; Eweis I; Wloch M; Livingston S; Seijo E; Cantor A; Lee JH; Beam CA; Sullivan D; Jove R; Muro-Cacho CA
Clin Cancer Res; 2006 Jan; 12(1):20-8. PubMed ID: 16397019
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
11. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Münster PN; Marchion DC; Basso AD; Rosen N
Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
[TBL] [Abstract][Full Text] [Related]
12. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Kalykaki A; Stournaras C; Mavroudis D; Georgoulias V
Breast Cancer Res; 2008; 10(5):R80. PubMed ID: 18822183
[TBL] [Abstract][Full Text] [Related]
14. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
16. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
17. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
18. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis.
Dubská L; Andera L; Sheard MA
FEBS Lett; 2005 Aug; 579(19):4149-58. PubMed ID: 16023111
[TBL] [Abstract][Full Text] [Related]
19. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]